Adicet Bio, Inc. (NASDAQ:ACET) Given Consensus Recommendation of “Moderate Buy” by Analysts

Adicet Bio, Inc. (NASDAQ:ACET) has earned a consensus recommendation of “Moderate Buy” from the five brokerages that are currently covering the firm, Marketbeat Ratings reports. Two analysts have rated the stock with a hold rating and three have assigned a buy rating to the company. The average 1-year price target among brokers that have issued a report on the stock in the last year is $7.50.

Several equities research analysts recently issued reports on ACET shares. StockNews.com cut shares of Adicet Bio from a “hold” rating to a “sell” rating in a report on Tuesday, November 19th. HC Wainwright reissued a “neutral” rating on shares of Adicet Bio in a report on Wednesday, February 5th. JMP Securities restated a “market perform” rating on shares of Adicet Bio in a research note on Thursday, February 6th. Finally, Wedbush reiterated an “outperform” rating and issued a $5.00 price objective on shares of Adicet Bio in a research note on Thursday, November 7th.

Adicet Bio Trading Down 6.8 %

NASDAQ ACET opened at $0.90 on Thursday. Adicet Bio has a 12 month low of $0.81 and a 12 month high of $3.47. The stock’s fifty day moving average price is $0.95 and its 200-day moving average price is $1.22. The stock has a market cap of $74.16 million, a P/E ratio of -0.53 and a beta of 1.86.

Institutional Trading of Adicet Bio

Hedge funds and other institutional investors have recently bought and sold shares of the stock. GSA Capital Partners LLP lifted its holdings in shares of Adicet Bio by 161.3% during the third quarter. GSA Capital Partners LLP now owns 39,208 shares of the company’s stock worth $56,000 after purchasing an additional 24,203 shares during the period. XTX Topco Ltd raised its position in Adicet Bio by 12.5% during the 3rd quarter. XTX Topco Ltd now owns 292,180 shares of the company’s stock worth $421,000 after buying an additional 32,392 shares during the last quarter. Marshall Wace LLP purchased a new position in Adicet Bio during the 2nd quarter worth approximately $43,000. Castleview Partners LLC acquired a new stake in Adicet Bio during the 3rd quarter valued at approximately $75,000. Finally, FMR LLC boosted its holdings in shares of Adicet Bio by 31.3% in the 3rd quarter. FMR LLC now owns 276,169 shares of the company’s stock valued at $398,000 after acquiring an additional 65,903 shares during the last quarter. Institutional investors own 83.89% of the company’s stock.

Adicet Bio Company Profile

Adicet Bio, Inc, a clinical stage biotechnology company, discovers and develops allogeneic gamma delta T cell therapies for autoimmune diseases and cancer. The company offers gamma delta T cells engineered with chimeric antigen receptors (CARs) to facilitate durable activity in patients. Its lead product candidate is ADI-001, an allogeneic gamma delta T cell therapy expressing a CAR targeting CD20, which is in Phase I clinical trial for the treatment of autoimmune diseases and relapsed or refractory aggressive B cell non-Hodgkin's lymphoma.